Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous HIV Gag-specific CD4+ T cells AGT103-T

A preparation of autologous, human immunodeficiency virus (HIV) Gag-specific, cluster of differentiation 4 (CD4)-positive T lymphocytes, with potential antiviral activity. Autologous HIV Gag-specific CD4+ T cells AGT103-T are prepared via ex vivo stimulation of autologous peripheral blood mononuclear cells (PBMCs) with Gag peptides, and the Gag-specific CD4+ T cells are transduced with the recombinant lentiviral vector AGT103 encoding inhibitory RNA targeting the HIV coreceptor C-C chemokine receptor type 5 (CCR5) and HIV sequences within the Vif/Tat coding regions. Upon administration, autologous HIV Gag-specific CD4+ T cells AGT103-T may prevent infection by CCR5- or CXCR4-tropic strains of HIV, reduce the depletion of CD4+ T cells upon HIV exposure and prevent latently-infected cells from releasing new HIV particles.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous HIV Gag-specific CD4-positive T lymphocytes AGT103-T
autologous HIV-specific CD4 T cells AGT103-T
Code name:AGT103-T
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search